Prognostic Value of NT-proBNP in Patients With Severe COVID-19 – PubMed
ClinicalTrials, NCT04292964. Registered 03 March 2020.
Related Articles
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial – PubMed
This trial confirms the superiority of the combination melphalan and prednisone plus thalidomide over melphalan and prednisone alone for prolonging survival in very elderly patients…
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study – PubMed
Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A Randomized Clinical Trial – PubMed
Despite high choline content in egg yolks, healthy participants consuming 4 eggs daily showed no significant increase in TMAO or platelet reactivity. However, choline bitartrate…
Financial Toxicity in Oncology, More Unanswered Questions – PubMed
Financial Toxicity in Oncology, More Unanswered Questions
Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia – PubMed
In patients treated in a PE, a neutropenic diet did not prevent major infection or death.
Early Management of Paediatric Wrist and Forearm Fractures in a Busy District General Hospital Emergency Department: A Retrospective Cohort Comparison Study and Audit of BOAST Guidelines – PubMed
Implementation of the Trust pathway in accordance with the BOAST guidelines along with staff education has standardized the practice at our Trust. It saved approximately…
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS – PubMed
This study supports the safety and tolerability of PrimeC in ALS. Biomarker analyses suggest early evidence of a biological effect. A placebo-controlled trial is required…
Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials – PubMed
Intensive low-density lipoprotein cholesterol lowering with a proprotein convertase subtilisin/kexin type 9 inhibitor combined with statin does not appear to increase the risk of new…
